An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Dry Eye
Interventions
DRUG

Optive MEGA-3 (OM3)

Eye Drops

Trial Locations (1)

38104-2211

Southern College of Optometry /ID# 262668, Memphis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY